Revolution Medicines, Inc. Cash and Cash Equivalents
Revolution Medicines, Inc. (RVMD) had Cash and Cash Equivalents of $815.43 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-05
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $815.43M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $440.94M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $383.75M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $217.44M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $815.43M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $440.94M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $383.75M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $217.44M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $402.44M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $333.55M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $543.06M 10-K · filed 2026-02-25 |
| 2024-09-30 | $201.26M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $275.71M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $288.43M 10-Q · filed 2025-05-07 |
| 2023-12-31 | $696.15M 10-K · filed 2026-02-25 |
| 2023-09-30 | $358.40M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $380.33M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $427.22M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $161.41M 10-K · filed 2025-02-26 |
| 2022-09-30 | $178.94M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $105.78M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $97.67M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $108.50M 10-K · filed 2024-02-26 |
| 2021-09-30 | $129.15M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $195.60M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $351.60M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $104.27M 10-K · filed 2023-02-27 |
| 2020-09-30 | $64.87M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $23.98M 10-Q · filed 2021-08-11 |
| 2020-03-31 | $182.67M 10-Q · filed 2021-05-10 |
| 2019-12-31 | $16.66M 10-K · filed 2022-02-28 |
| 2019-09-30 | $21.82M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $85.47M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $62.76M 10-Q · filed 2020-05-14 |
| 2018-12-31 | $69.59M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |